Received Aug 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVB064A | IM / LA |
a female patient received the liquid conjugate component only of Menveo on 14-JUL-2025; a female patient received the liquid conjugate component only of Menveo on 14-JUL-2025; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 12-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB064A, expiry date 31-DEC-2025) for prophylaxis. On 14-JUL-2025, the patient received Menveo (intramuscular, left deltoid). On 14-JUL-2025, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: a female patient received the liquid conjugate component only of Menveo on 14-JUL-2025) and inappropriate dose of vaccine administered (Verbatim: a female patient received the liquid conjugate component only of Menveo on 14-JUL-2025). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 17-JUL-2025 The reporter was a nurse who called to report that a male patient had received only the liquid conjugate component of Menveo, which led to Inappropriate preparation of medication and Inappropriate dose of vaccine administered. This was 1 of 3 linked case reported by the same reporter.; Sender's Comments: US-GSK-US2025091789:same reporter, Different patient, 3 of 3 report